Form 8.3 - The Allergy Therapeutics Plc
LONDON, June 23, 2023--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Ta...
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| 0.06 | |
| 0.06 | |
| - | |
| 0.06 | |
| 0.06 | |
| 0.01-0.175 | |
| 307 M | |
| 4 766 M | |
| 53 258 K | |
| -0.013 | |
| 1.465 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
LONDON, June 23, 2023--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Ta...
LONDON, June 22, 2023--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Ta...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: